Table 1.
Visit No. | T0 | Weekly treatment | T1 | T2 | |||||||
Week No. | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 24 |
Data provided by the patient | |||||||||||
Pain intensity (VAS 100 mm) | X | X | X | ||||||||
Multidimensional pain evaluation (MPQ-SV) | X | X | X | ||||||||
Quality of life (SF-12) | X | X | X | ||||||||
Analgesics and antiinflammatory drugs prescribed | X | X | X | ||||||||
Sociodemographic variables | X | ||||||||||
Credibility and expectations | X | ||||||||||
Improvement perceived by the patient | X | ||||||||||
Assessment of blinding effectiveness | X | ||||||||||
Data provided by the therapist | |||||||||||
Multidimensional pain evaluation (LT) | X | X | X | X | X | X | X | X | X | X | X |
Auricular points used | X | X | X | X | X | X | X | X | X | ||
Adverse events | X | X | X | X | X | X | X | X | X | ||
Economic evaluation | |||||||||||
Direct and indirect costs: healthcare professionals and patients | X | X | X |
VAS 100 mm: Visual analogue scale (0–100 mm); MPQ-SV: McGill Pain Questionnaire, Spanish version; LT: Lattinen test